Cempra Inc. was Downgraded to a Hold Rating at Raymond JamesBy Jason Carr
According to TipRanks.com, Raymond is a top 100 analyst with an average return of 34.9% and a 67.3% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Karyopharm Therapeutics, and Amag Pharmaceuticals.
Cempra Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $31.
The company has a one year high of $34.24 and a one year low of $8.30. Currently, Cempra Inc. has an average volume of 1.03M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CEMP in relation to earlier this year.
Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its antibiotic candidates includs Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC.